Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.
Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in Edison, New Jersey, USA.
Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here
|Q3 2015 Interim Report
|Q3 2015 Presentation